Patients with transfusion-dependent beta-thalassemia require lifelong regular blood transfusions to manage severe anemia and suppress ineffective erythropoiesis. However, repeated red blood cell transfusions inevitably cause systemic iron overload, leading to organ damage in the liver, heart, and endocrine glands. To mitigate iron toxicity, daily oral iron chelation therapy with agents like deferasirox has become the standard of care worldwide. While effective at removing excess iron, clinicians must maintain vigilance regarding potential deferasirox ocular complications, which can compromise vision if left undetected.

Pathophysiology of Ocular Changes in Beta-Thalassemia

Ocular complications in beta-thalassemia stem from a complex interaction between chronic tissue hypoxia, systemic iron overload, and the toxic effects of iron chelation therapy. Unchelated iron generates reactive oxygen species via the Fenton reaction, inducing oxidative damage in the retinal pigment epithelium, ciliary body, and crystalline lens. Conversely, excessive chelation therapy can deplete essential trace metals such as zinc and copper, disrupting retinal neurochemistry and metabolic pathways in ocular tissues. Consequently, patients may experience a spectrum of ocular manifestations ranging from mild lenticular opacities to severe pigmentary retinopathy and optic neuropathy.

Clinical Findings and Prevalence of Deferasirox Ocular Complications

Recent clinical investigations have highlighted specific ocular changes among patients receiving long-term deferasirox therapy. In a cross-sectional study evaluating 75 transfusion-dependent beta-thalassemia patients on deferasirox, bilateral cataracts were identified in 9.3% of the cohort. Additionally, comprehensive ophthalmic examinations revealed that best-corrected visual acuity correlated positively with ambient hemoglobin concentrations. Patients maintaining higher steady-state hemoglobin levels demonstrated superior visual outcomes, emphasizing the beneficial role of adequate transfusion regimens in sustaining ocular microvascular perfusion and retinal health.

Ophthalmic Monitoring Protocols for Chelated Patients

Given the insidious onset of drug-related and iron-induced ocular toxicities, structured ophthalmologic surveillance is paramount for all individuals on deferasirox. Clinicians should conduct a comprehensive baseline ocular assessment before initiating chelation therapy, followed by annual routine checkups. This assessment should encompass best-corrected visual acuity, slit-lamp biomicroscopy, dilated fundus examination, optical coherence tomography, and fundus autofluorescence imaging. If patients report sudden visual disturbances, color vision alterations, or progressive blurring, clinicians must immediately perform detailed retinal diagnostics and adjust the chelation regimen.

Balancing Chelation Efficacy and Ocular Safety

Optimizing chelation therapy demands striking a delicate balance between preventing heavy iron-mediated organ failure and avoiding drug-induced ocular toxicity. When serum ferritin levels decline below target thresholds, the risk of chelation toxicity rises significantly because deferasirox binds trace minerals instead of excess iron. Therefore, clinicians must routinely monitor serum ferritin, liver iron concentration, and systemic iron saturation markers to calibrate deferasirox dosages appropriately. If verified drug-related ocular changes emerge, temporary dose reduction or drug cessation typically stabilizes or reverses the observed visual deficits.

Interdisciplinary Care Strategies in Clinical Practice

Managing beta-thalassemia successfully requires seamless collaboration between hematologists, ophthalmologists, and primary care physicians. Hematology teams must emphasize therapeutic adherence while actively questioning patients regarding visual symptoms during monthly transfusion visits. Likewise, ophthalmologists should remain well versed in the distinctive retinal and lenticular presentations associated with oral iron chelators. Through coordinated surveillance and timely multidisciplinary intervention, healthcare providers can preserve vision and substantially enhance overall quality of life for individuals with transfusion-dependent hemoglobinopathies.

Frequently Asked Questions

What are the primary deferasirox ocular complications observed in clinical practice?

The most frequently reported ocular complications include early-onset lenticular opacities or bilateral cataracts, retinal pigment epithelial changes, maculopathy, and optic neuropathy. Patients may occasionally experience decreased visual acuity, color vision defects, or impaired night vision, necessitating prompt specialist assessment and diagnostic testing.

How frequently should patients receiving deferasirox undergo ophthalmologic examinations?

Every patient initiating deferasirox therapy should undergo a comprehensive baseline ophthalmological evaluation, including visual acuity testing, slit-lamp biomicroscopy, and dilated fundoscopy. Subsequently, routine follow-up examinations should occur annually, or earlier if patients report new visual symptoms, photophobia, or sudden blurring.

Can ocular toxicity caused by deferasirox be reversed after drug adjustment?

Yes, many early-stage ocular toxicities and mild visual deficits demonstrate stabilization or partial reversibility following deferasirox dose reduction or temporary drug discontinuation. Close monitoring by a multidisciplinary team ensures timely dose adjustments before irreversible retinal or optic nerve damage occurs.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Refer to the latest local and national guidelines for clinical practice.

References

1. Medghalchi A et al. Ocular Complications in Patients With Transfusion-Dependent Beta-Thalassemia Receiving Deferasirox: A Cross-Sectional Study. Health Sci Rep. 2026 Aug undefined. doi: 10.1002/hsr2.73053. PMID: 42609502.
2. Porter JB et al. Iron overload and chelation therapy in transfusion-dependent thalassaemias: current status and future perspectives. Br J Haematol. 2023;201(5):811-825.
3. Taher AT et al. Management of iron overload in transfusion-dependent beta-thalassemia: consensus guidelines. Ann Hematol. 2022;101(7):1425-1440.